Overview
Murali Doraiswamy MBBS FRCP is Professor of Psychiatry and Professor in Medicine at Duke University School of Medicine where he is a highly cited physician scientist at the Duke Institute for Brain Sciences. He is also a Senior Fellow at the Duke Center for the Study of Aging and an Affiliate Faculty at the Duke Center for Precision Medicine and Applied Genomics as well as the Duke Microbiome Center. He directs a clinical trials unit that has been involved in the development of many modern diagnostic tests, apps, algorithms, and therapeutics in wide use today. Prof Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups including the NIH, FDA, and WHO as well as numerous life science companies. He has served as the chair of the World Economic Forum’s Global Agenda Council on Brain Research and co-chaired the innovation advisory council for one of the world’s largest social impact funds dedicated to promoting innovative solutions to reverse age related disorders. He has lectured at leading global forums to advance the forefront of aging and neuroscience research. Moreover as an investigator on numerous landmark trials and co-author on more than 400 publications, he has received several awards in recognition of his scientific work. Additionally, he is a leading advocate for increasing funding for brain and behavioral research to help address great looming challenges in society posed by modern developments in the 21st century. His research has been featured in media outlets such as BBC, The New York Times, Scientific American, The Wall Street Journal, National Public Radio, CBS Evening news, The Dr Oz Show, Oprah, and TIME. He has appeared in acclaimed documentaries such as (Dis)Honesty: The Truth about Lies and Mysteries of the Brain. He is the co-author of a popular book The Alzheiemr's Action Plan. Prof. Doraiswamy also serves on the board of several global charities.
Current Appointments & Affiliations
Recent Publications
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.
Journal Article CNS Drugs · December 1, 2025 Amyloid-plaque reduction is currently the only recognized surrogate outcome for Alzheimer's disease (AD) trials, allowing accelerated approval of plaque-clearing amyloid antibodies. However, plaque reduction does not facilitate the development of new non-p ... Full text Link to item CiteDeveloping Topics
Journal Article Alzheimer S Dementia the Journal of the Alzheimer S Association · December 1, 2025 BACKGROUND: Valiltramiprosate/ALZ-801, an oral inhibitor of amyloid oligomer formation, was evaluated in a Phase 3 trial in APOE4/4 subjects with Early AD. While the study did not meet its primary clinical endpoint, volumetric MRI (vMRI) showed significant ... Full text CiteDeveloping Topics
Journal Article Alzheimer S Dementia the Journal of the Alzheimer S Association · December 1, 2025 BACKGROUND: Valiltramiprosate (ALZ-801), an oral inhibitor of amyloid oligomer formation, was evaluated in a Phase 3 trial in APOE4/4 homozygotes with Early AD (Abushakra, 2024); the topline results being presented at this meeting (Power, 2025). While the ... Full text CiteRecent Grants
Duke University Psychiatry Physician-Scientist Residency Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Mental Health · 2024 - 2029Cognitive training and neuroplasticity in Mild Cognitive Impairment
ResearchPrincipal Investigator · Awarded by Columbia University · 2017 - 2029Plasma proteins, sex and Alzheimer's disease: Proteome-wide analyses of the UK Biobank and Framingham Heart Study
ResearchPrincipal Investigator · Awarded by Cure Alzheimer's Fund · 2025 - 2027View All Grants